Rydar Equities’s Bright Minds Biosciences DRUG Stock Holding History

Rydar Equities’s Portfolio DRUG Stock Details DRUG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.16K	Buy	+80	New	+$5.65K	﹤0.01%	369

Other funds holding DRUG

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Rydar Equities's DRUG Position: Q3 2026 in Review

Rydar Equities opened a new position in Bright Minds Biosciences (DRUG) in Q3 2026: 80 shares worth $4.16K. The stake represents ﹤0.01% of the portfolio and ranks #369 among its holdings.

6 funds tracked by Wall St. Rank hold DRUG as of Q3 2026.

Rydar Equities held 80 shares of Bright Minds Biosciences worth $4.16K as of Q3 2026.
Bright Minds Biosciences was a new Rydar Equities position in Q3 2026.
Bright Minds Biosciences made up ﹤0.01% of Rydar Equities's portfolio in Q3 2026, its #369 holding.
6 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q3 2026.

Based on Rydar Equities's 13F filing for Q3 2026, filed 13 Oct 2026.